VNDA Vanda Pharmaceuticals Inc.

13.53
+0.59  (+5%)
Previous Close 12.94
Open 12.94
Price To Book 2.43
Market Cap 720,795,705
Shares 53,273,888
Volume 650,596
Short Ratio
Av. Daily Volume 633,713
Stock charts supplied by TradingView

NewsSee all news

  1. Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies

    WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial initiated 2Q 2019.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
CRL issued August 19, 2019.
HETLIOZ (tasimelteon)
Jet Lag Disorder
sNDA filing due 4Q 2019.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 data due 1H 2020.
Tradipitant
Atopic dermatitis
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies
Phase 3 trial to be initiated 3Q 2019.
Tradipitant
Motion sickness
Randomized trial to commence in 2019.
Fanapt
Bipolar Disorder
Phase 2 trial to be initiated 3Q 2019.
HETLIOZ (tasimelteon)
Delayed sleep phase disorder (DSPD)

Latest News

  1. Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies

    WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high